Safety and Clinical Efficacy of PD-1 on Advanced Primary Hepatocellular Carcinoma

Objective  To observe the short-term clinical effect and total survival of advanced hepatocellular carcinoma patients treated with PD-1.

Methods  We retrospectively analyzed the clinical data of 48 patients with advanced hepatocellular carcinoma treated with PD-1 monoclonal antibody (observation group) and 55 patients with advanced hepatocellular carcinoma treated with apatinib mesylate(control group). Short-term clinical effect, overall survival and adverse reactions were analyzed.

Results  The AFP, ALT, AST, ECOG, Child-Paugh score, objective remission rate and disease control rate in the observation group were better than those in the control group (P < 0.05), and the overall survival in the observation group (95%CI: 7.24-8.64 months) was significantly longer than that in the control group (95%CI: 5.13-6.39 months) (P < 0.05). There were significant differences in rashes, nausea, vomiting and adverse reactions of hypertension between two groups (P < 0.05).

Conclusion  Compared with apatinib mesylate, PD-1 could improve the short-term clinical efficacy and prolong the overall survival of patients with advanced hepatocellular carcinoma.